Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) have been given an average rating of “Hold” by the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.50.
MGNX has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MacroGenics in a report on Tuesday, November 3rd. Citigroup started coverage on shares of MacroGenics in a research report on Friday, October 23rd. They set a “positive” rating on the stock. B. Riley Financial upped their price target on shares of MacroGenics from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Finally, Wall Street Zen lowered shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Saturday.
View Our Latest Report on MGNX
MacroGenics Trading Down 5.5%
Shares of MGNX opened at $2.05 on Wednesday. MacroGenics has a 12 month low of $1.32 and a 12 month high of $5.08. The stock has a fifty day moving average price of $3.24 and a 200-day moving average price of $3.43. The firm has a market cap of $131.02 million, a PE ratio of -2.53 and a beta of 1.33.
Hedge Funds Weigh In On MacroGenics
Several hedge funds have recently made changes to their positions in MGNX. Legal & General Group Plc purchased a new position in shares of MacroGenics in the second quarter worth about $28,000. State of Wyoming lifted its holdings in shares of MacroGenics by 201.0% during the third quarter. State of Wyoming now owns 7,518 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 5,020 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of MacroGenics during the first quarter worth about $39,000. Sanders Morris Harris LLC acquired a new stake in shares of MacroGenics during the third quarter worth about $48,000. Finally, Two Sigma Securities LLC purchased a new stake in MacroGenics in the second quarter valued at approximately $63,000. 96.89% of the stock is owned by institutional investors and hedge funds.
MacroGenics Company Profile
MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.
Further Reading
- Five stocks we like better than MacroGenics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.
